Abstract Library

#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ghaleb N

Authors: Ghaleb N, Dick R, Heraghty N, Zwane-Allen P, Vadrucci M,

Keywords: Nuclear Medicine, Hybrid Imaging, Relapse Therapy, PRRT, Survival, Toxicity,

#1300 Staging of Neuroendocrine Tumors: Value of Hybrid Imaging With 111In- Pentetreotide

Introduction: Neuroendocrine tumors (NET) are rare and can occur anywhere in the body. Ninety-eight percent of these tumors express the type 2 of somatostatin receptors, making possible the functional imaging of NET. 111In-labelled pentetreotide specifically binds to somatostatin receptors, with particular affinity to subtypes 2 and 5.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Khamla E

Authors: Ben Sellem D, Khamla E, Ben Slimene M,

Keywords: Neuroendocrine tumor,